Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professor Sarah Gilbert has been awarded the Royal Society for Arts, Manufactures and Commerce’ (RSA) Albert Medal for her work on the Oxford vaccine.

Oxford skyline and Radcliffe Camera © Oxford University Images / Whitaker Studio

The lead researcher on the Oxford vaccine team, Professor Sarah Gilbert is Professor of Vaccinology in the Nuffield Department of Medicine at the University of Oxford. She is the Oxford Project Leader for ChAdOx1 nCoV-19, a vaccine against the novel coronavirus, SARSCoV-2, with approval for use in many countries around the world.

The RSA Albert Medal is awarded annually to recognise the creativity and innovation of individuals and organisations working to resolve the challenges of our time. Professor Gilbert receives the 2021 honour for her services to collaborative innovation for the global common good. She is the 156th recipient of the medal, which was instituted in 1864 as a memorial to Prince Albert, former President of the Society.

Previous recipients range from scientists to artists to social campaigners: they include Alexander Graham Bell in 1902 for the invention of the telephone; Marie Curie in 1910 for the discovery of radium; Stephen Hawking in 1999 for improving public awareness of physics; and Tim Berners-Lee in 2002 for the creation of the World Wide Web.

Read the full story on the University of Oxford website.

Similar stories

Major grant to strengthen research and benefit patients

Oxford University Hospitals (OUH) has made a grant of £11.5 million to the University of Oxford, which the University will match with other funding, to allow the development of major clinical research facilities which have the potential to support the introduction of innovative and ground-breaking treatments for patients.

Dr Lennard Lee awarded ACP McElwain Prize for contributions to medical oncology

Dr Lee (Department of Oncology) received the award to acknowledge his contributions during the COVID-19 pandemic, through the establishment of the UK Coronavirus Cancer Monitoring Project.

Oxford joins forces with 11 universities to launch social impact investment fund

The University of Oxford has joined forces with 11 leading universities to create Impact 12, an impact investment fund to support mission-led university ventures.

Ivermectin to be investigated as a possible treatment for COVID-19 in the PRINCIPLE trial

From today, ivermectin is being investigated in the UK as part of the Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses (PRINCIPLE), the world’s largest clinical trial of possible COVID-19 treatments for recovery at home and in other non-hospital settings.

Potential for radiotherapy and VTP multimodality therapy for prostate cancer

A recent collaborative study from the University of Oxford has investigated the potential benefit of a combined therapy approach to prostate cancer treatment, using radiotherapy and vascular targeted photodynamic therapy (VTP), which could lead to first-in-man early phase clinical trials.

Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study

A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.